The prognostic role of baseline 18F-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy

Basit Öğe Kaydı
dc.contributor.authorCan, Canan
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorKömek, Halil
dc.contributor.authorGündogan, Cihan
dc.contributor.authorUrakçı, Zuhat
dc.contributor.authorIşıkdoǧan, Abdurrahman
dc.date.accessioned2024-04-24T17:56:10Z
dc.date.available2024-04-24T17:56:10Z
dc.date.issued2022
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractObjective: This study aimed to determine the prognostic role of baseline maximum standardized uptake value (SUVmax) obtained by pretreatment PET/CT and the change in SUVmax (?SUVmax [%]) in patients with axillary lymph node–positive breast cancer receiving neoadjuvant chemotherapy (NAC). Methods: One hundred and eighty patients with baseline SUVmax and 121 patients with SUVmax measurement after treatment were evaluated in the study. The baseline SUVmax value of the breast (SUVmaxBI) and axilla (SUVmaxAI) and the change in the SUVmax of the breast (?SUVmaxB) and axilla (?SUVmaxA) were measured. The optimal cut-off value of SUVmax and ?SUVmax were determined by ROC curve analysis. Disease-free survival (DFS) and overall survival (OS) were calculated using Kaplan–Meier curves. Results: ?SUVmaxB, pCRB, pCRA, and pCR parameters were found to be associated with relapse (p < 0.001, p = 0.033, p = 0.016, and p = 0.013, respectively). ?SUVmaxB and SUVmaxAI were associated with mortality (p = 0.001 and p = 0.006, respectively). Multiple Cox regression analyses revealed that ?SUVmaxB value was an independent prognostic factor for relapse and mortality (p = 0.013 and p = 0.010, respectively). Conclusion: The results showed that ?SUVmaxB was an independent prognostic factor for relapse and mortality in patients with axillary lymph node–positive breast cancer who received NAC.en_US
dc.identifier.citationCan, C., Akdeniz, N., Kömek, H., Gündogan, C., Urakçı, Z. ve Işıkdoǧan, A. (2022). The prognostic role of baseline 18F-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy. Revista Espanola de Medicina Nuclear e Imagen Molecular, 41(1), 3-10.
dc.identifier.doi10.1016/j.remn.2021.02.010
dc.identifier.endpage10en_US
dc.identifier.issn2253-654X
dc.identifier.issue1en_US
dc.identifier.pmid34353770en_US
dc.identifier.scopus2-s2.0-85111743088en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage3en_US
dc.identifier.urihttps://doi.org/10.1016/j.remn.2021.02.010
dc.identifier.urihttps://hdl.handle.net/11468/23346
dc.identifier.urihttps://www.sciencedirect.com/science/article/abs/pii/S2253654X21000512?via%3Dihub
dc.identifier.volume41en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorUrakçı, Zuhat
dc.institutionauthorIşıkdoǧan, Abdurrahman
dc.language.isoenen_US
dc.publisherEdiciones Doyma, S.L.en_US
dc.relation.ispartofRevista Espanola de Medicina Nuclear e Imagen Molecularen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast canceren_US
dc.subjectFdg Pet/Cten_US
dc.subjectNeoadjuvant chemotherapyen_US
dc.subjectPrediction responseen_US
dc.subjectPrognosisen_US
dc.subjectSuvmax changeen_US
dc.titleThe prognostic role of baseline 18F-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapyen_US
dc.title.alternativeEl papel pronóstico del SUVmáx basal y cambio del SUVmáx en la PET/TC con18F-FDG en pacientes con cáncer de mama con ganglios positivos que reciben quimioterapia neoadyuvanteen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu